Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults
Phase 1
Not yet recruiting
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo Solution
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Pharmosa Biopharm Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06429930
- Locations
- 🇳🇿
NZCR Ltd (New Zealand Clinical Research), Christchurch, New Zealand
Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults
Phase 1
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: L608 Inhalation SolutionDrug: Placebo solution
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Pharmosa Biopharm Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05938946
- Locations
- 🇦🇺
CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606
Phase 1
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: L606 (Liposomal Treprostinil) Inhalation Solution 51ugDevice: L606 Inhalation SystemOther: Placebo Solution
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Pharmosa Biopharm Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04041648
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath